Immatics (IMTX) Liabilities and Shareholders Equity (2019 - 2026)
Immatics (IMTX) posted Liabilities and Shareholders Equity of $654.6 million for Q4 2025, up 7.98% sequentially from $606.2 million in Q3 2025, and down 12.01% YoY from $743.9 million in Q4 2024.
Analysis
Immatics (IMTX) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Immatics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $654.6 million in Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 12.01% year-over-year to $654.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.6 billion (down 6.68% YoY) and the FY2025 annual result came in at $635.3 million, down 15.68% from the prior year.
- Liabilities and Shareholders Equity rose to $654.6 million in Q4 2025 per IMTX's latest filing, from $606.2 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $743.9 million in Q4 2024 and troughed at $199.8 million in Q4 2021.
- A 5-year average of $484.2 million and a median of $461.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- The widest YoY moves for Liabilities and Shareholders Equity: up 119.32% in 2021, down 34.2% in 2021.
- Over 5 years, Liabilities and Shareholders Equity stood at $199.8 million in 2021, then surged by 108.26% to $416.1 million in 2022, then surged by 31.87% to $548.7 million in 2023, then soared by 35.58% to $743.9 million in 2024, then decreased by 12.01% to $654.6 million in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $654.6 million, $606.2 million, and $642.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | 564.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 564.60 Mn |
| Mar 31, 2026 | 636.02 Mn |
| Dec 31, 2025 | 654.58 Mn |
| Sep 30, 2025 | 606.22 Mn |
| Jun 30, 2025 | 642.16 Mn |
| Mar 31, 2025 | 674.99 Mn |
| Dec 31, 2024 | 743.90 Mn |
| Sep 30, 2024 | 633.93 Mn |
| Jun 30, 2024 | 675.17 Mn |
| Mar 31, 2024 | 709.53 Mn |
| Dec 31, 2023 | 548.69 Mn |
| Sep 30, 2023 | 476.20 Mn |
| Jun 30, 2023 | 446.66 Mn |
| Mar 31, 2023 | 406.25 Mn |
| Dec 31, 2022 | 416.08 Mn |
| Sep 30, 2022 | 357.22 Mn |
| Jun 30, 2022 | 393.00 Mn |
| Mar 31, 2022 | 316.70 Mn |
| Dec 31, 2021 | 199.79 Mn |
| Sep 30, 2021 | 234.57 Mn |